5 Retatrutide Side Effects: What Clinical Trials Reveal About the Triple Agonist's Safety Profile

Retatrutide (LY3437943), Eli Lilly's investigational triple-agonist (GIP/GLP-1/glucagon) therapy, has captured global attention for its unprecedented weight loss results — up to 30.3% in the pivotal TRIUMPH-1 Phase 3 trial. But with greater potency comes a distinct side effect profile that patients and clinicians need to understand. As the drug advances toward regulatory filings with the FDA and Health Canada, here is what the clinical trial data reveal about retatrutide's five most important side effect categories. ## 1. Gastrointestinal Adverse Events (The Most Common) Gastrointestinal (GI) side effects are the most frequently reported adverse events with retatrutide, consistent with other incretin-based therapies. In the Phase 2 dose-finding trial published in the *New England Journal of Medicine*, nausea occurred in 31% to 54% of participants across dosing groups, with vomiting in 9% to 33%, and diarrhoea in 17% to 33% of participants. These effects are dose-dependent and most pronounced during the initial dose-escalation phase. The TRIUMPH-1 protocol employed a gradual 24-week dose-escalation schedule specifically to mitigate GI tolerability — a strategy that appears to have been effective, as discontinuation rates due to adverse events in the 48-week data were lower than in faster-escalation regimens. Canadian clinicians should note that GI tolerability is the primary reason patients discontinue GLP-1 class medications in real-world settings. The dose-escalation protocol for retatrutide, if approved, will require careful patient education, antiemetic management strategies, and realistic expectations about the adjustment period. ## 2. Decreased Appetite and Weight-Loss Related Symptoms Unlike adverse events in the traditional sense, decreased appetite is a pharmacodynamic effect of retatrutide's mechanism — it is, in fact, the pathway through which the drug drives weight loss. Clinical trial data consistently report reduced appetite in the majority of participants, with some experiencing it as a moderate to severe effect during the first several weeks of treatment. Reduced food intake can lead to: - Fatigue and low energy during the initial adjustment period - Constipation, particularly if fluid and fibre intake are not maintained - Nutritional concerns requiring monitoring in patients with pre-existing deficiency risks - Difficulty maintaining adequate protein intake, which may affect lean body mass preservation during weight loss These effects tend to diminish over time as the body adapts, but some patients may experience persistent appetite suppression that requires active dietary management. ## 3. Injection Site Reactions As a subcutaneously injected medication — likely administered weekly, similar to tirzepatide — retatrutide can cause injection site reactions. In clinical trials, these have included: - Mild erythema (redness) at the injection site, typically resolving within hours - Localized itching or swelling, usually self-limiting - Rare cases of injection site discomfort requiring rotation of injection sites These reactions are generally mild to moderate and do not require treatment discontinuation. Patients are advised to rotate injection sites (abdomen, thigh, upper arm) and avoid injecting into areas of active skin irritation. ## 4. Heart Rate Changes (Glucagon Receptor Activation) Retatrutide's unique glucagon receptor agonism — the feature that distinguishes it from dual-agonist tirzepatide — can produce a measurable increase in resting heart rate. Phase 2 data showed a mean increase of 2 to 6 beats per minute in retatrutide-treated participants compared to placebo, an effect that was more pronounced at higher doses. This finding triggered inclusion of cardiac monitoring protocols in the TRIUMPH program, including Holter monitoring in TRIUMPH-1. No significant cardiovascular safety signals — no increase in arrhythmias, no QTc prolongation — have been reported to date. The heart rate increase appears to be most prominent during dose escalation and tends to attenuate over time on a stable dose. In Canada's publicly funded healthcare system, where primary care physicians would manage the majority of retatrutide prescriptions, this heart rate effect means baseline cardiovascular assessment — including heart rate measurement and potentially an ECG — should be considered before initiating therapy. Patients with pre-existing cardiac conditions may require specialist consultation. ## 5. Serious Adverse Events and Safety Monitoring Beyond the common side effects, retatrutide's clinical development program has identified several areas requiring ongoing safety surveillance: **Gallbladder and biliary events:** As with all GLP-1 receptor agonists, retatrutide carries a potential risk of gallstone formation and cholecystitis, particularly during rapid weight loss. The TRIUMPH program includes monitoring for biliary adverse events. **Pancreatitis:** A known class risk for incretin-based therapies. The retatrutide trials have not identified a signal above the expected background rate, but the drug is contraindicated in patients with a history of pancreatitis until more data are available. **Liver safety:** The Victoria public health warning in June 2026, which reported six cases of liver damage potentially associated with retatrutide use, underscores the importance of hepatic monitoring. While the TRIUMPH program includes regular liver function testing, and retatrutide is also being studied for metabolic dysfunction-associated steatohepatitis (MASH), these real-world signals from unregulated use highlight the risks associated with obtaining the drug outside clinical trials. **Discontinuation due to adverse events:** In the Phase 2 trial, discontinuation rates due to adverse events ranged from 7% to 16% across dosing groups, compared to 5% for placebo. In TRIUMPH-1, the 48-week discontinuation rate due to adverse events was approximately 8% in the highest-dose arm. ## Canadian Context For Canadians following retatrutide's development, understanding its side effect profile is crucial for several reasons: **Primary care readiness:** Canada's obesity care is predominantly delivered by family physicians rather than obesity specialists. When retatrutide eventually receives Health Canada approval, primary care providers will need clear guidelines on monitoring for GI tolerability, heart rate changes, and biliary symptoms. Clinical practice guidelines from Diabetes Canada and Obesity Canada will need updating to incorporate triple-agonist-specific safety monitoring recommendations. **Cost and access implications:** Retatrutide's side effect profile — particularly the GI tolerability that leads to discontinuation in some patients — should factor into pCPA (pan-Canadian Pharmaceutical Alliance) negotiations. If a meaningful proportion of patients cannot tolerate the drug, cost-effectiveness analyses must account for discontinuation rates and the need for dose-escalation support resources. **Health Canada Special Access Programme risks:** The Victoria liver damage cases serve as a stark reminder of the dangers of obtaining retatrutide through unregulated channels, including some SAP requests that may bypass standard safety monitoring. Canadians should only access retatrutide through approved clinical trials or, once approved, through regulated prescription channels with appropriate medical supervision. **Regulatory timing:** The FDA and Health Canada submissions are expected in late 2026 to early 2027. The side effect profile outlined above will form the basis of the prescribing information, including contraindications, warnings, and the required Risk Evaluation and Mitigation Strategy (REMS) in the United States. ## Sources - Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." *New England Journal of Medicine* 2023; 389:514-526. DOI: 10.1056/NEJMoa2301972 - Eli Lilly. "TRIUMPH-1 Phase 3 Topline Results." May 21, 2026. Lilly Investor Relations - ClinicalTrials.gov. NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2) - Health Victoria. "Warning: Six Cases of Liver Damage Potentially Associated with Retatrutide." June 2026 - Ro. "5 Retatrutide Side Effects: What We Know From Clinical Trials." July 21, 2026. *ro.co* - Medscape. "Retatrutide Data Show Dramatic Weight Loss and Broad Comorbidity Benefits." June 2026 - Diabetes Canada. "Clinical Practice Guidelines for Obesity Management." Updated 2025 - Obesity Canada. "Obesity Treatment Guidelines." 2025 Edition